Array
(
[1600234714] => Array
(
[wordfence_batchReportBlockedAttempts] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] =>
[args] => Array
(
)
)
)
)
[1600234773] => Array
(
[wp_privacy_delete_old_export_files] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1600234874] => Array
(
[wordfence_processAttackData] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] =>
[args] => Array
(
)
)
)
)
[1600235281] => Array
(
[wpm_update_stats] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1600237485] => Array
(
[recovery_mode_clean_expired_keys] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1600237490] => Array
(
[wp_site_health_scheduled_check] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => weekly
[args] => Array
(
)
[interval] => 604800
)
)
)
[1600237614] => Array
(
[wordfence_hourly_cron] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1600240112] => Array
(
[ai1wm_storage_cleanup] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1600246171] => Array
(
[wp_scheduled_auto_draft_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1600251311] => Array
(
[delete_expired_transients] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1600251352] => Array
(
[wpseo-reindex-links] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1600252014] => Array
(
[wordfence_daily_cron] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1600263126] => Array
(
[wp_update_themes] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
[wp_update_plugins] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1600263874] => Array
(
[wp_scheduled_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1600266553] => Array
(
[wp_version_check] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1600269473] => Array
(
[wp_session_garbage_collection] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1600272424] => Array
(
[akismet_scheduled_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1600275411] => Array
(
[yoast_tracking] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1600350600] => Array
(
[wordfence_start_scheduled_scan] => Array
(
[2a04b39f8fc7eef97dccfc3e882e6ef0] => Array
(
[schedule] =>
[args] => Array
(
[0] => 1600350600
)
)
)
)
[1600609800] => Array
(
[wordfence_start_scheduled_scan] => Array
(
[e952a26b7e458830f5cf6cb4cc428a6f] => Array
(
[schedule] =>
[args] => Array
(
[0] => 1600609800
)
)
)
)
[1600696800] => Array
(
[wordfence_email_activity_report] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] =>
[args] => Array
(
)
)
)
)
[1601157627] => Array
(
[publish_future_post] => Array
(
[aa3f9c41dd8e97586795881a0c603b8d] => Array
(
[schedule] =>
[args] => Array
(
[0] => 472787
)
)
)
)
)
Etiquetas: ADN, Anticuerpos monoclonales, Bioequivalencia, Biofármacos, Biofármacos en España, Biosimilares, Bioterapia, Consejo general de Cólegios oficiales de farmacéuticos, DNA, España, Fármaco, Febrero 2011, Madrid, Medicamento, Medicamentos biotecnológicos, Mercado biofarmacéutico, Mercado biofarmacéutico en España, Panorama, Panorama de los biofármacos, Punto Farmacológico, salud, Sanidad.
Etiquetas: 28 mayo 2007, Ácido desoxirribonucleico, ADN, Agustí Cerdà Argent, Alejandro Ballestero de Diego, Análisis del ADN, Bases de datos policial, Begoña Lasagabáster Olazábal, Boletín Oficial, Carlos González Serna, Condenar al culpable de un delito, Congreso de los Diputados, Cortes Generales, Dependencia orgánica, Determinación de relaciones de parentesco, Emilio Olabarría Muñoz, Identidad de la persona, Identificación de cadáveres, Identificar, Imprenta Nacional BOE, Información genética, Instituto Nacional de Toxicología y Ciencias Forenses, Isaura Navarro Casillas, Josep María Guinart Solá, Juan Carlos Corcuera Plaza, Laboratorios acreditados, Laboratorios de las Fuerzas y Cuerpos de Seguridad del Estado, Ley de Enjuiciamiento Criminal, Luis Mardones Sevilla, Madrid, Manuel Alba Navarro, María del Carmen Matador de Matos, Proyecto de Ley, Reguladora de la base de datos policial sobre identificadores obtenidos a partir del ADN, Remisión de los datos, salud, Sanidad, Sebastián Fuentes Guzmán, Tipos de datos, Toma de muestras y fluidos, Uso y cesión de los datos contenidos en la base de datos.
Etiquetas: 2007, ADN, Cáncer, Consorcio Internacional del Genoma del Cáncer, Desarrollo científico-técnico del proyecto, El papel de España en el marco del ICGC, Estudios funcionales y clínicos, Financiación y gestión del proyecto, Genoma Humano, Gobierno de España, ICGC, International Cancer Genome Consortium, Investigador internacional, L.I.A., Líneas Instrumentales de Actuación, Madrid, Objetivos científicos del proyecto, Participación de España en el Consorcio Internacional del Genoma del Cáncer, Red Temática de Investigación Cooperativa en Cáncer, RTICC, TCGA, The Cancer Genome Atlas, Tumor.
.gif)